Skip to main content
AprilBio Co.,Ltd. logo

AprilBio Co.,Ltd. — Investor Relations & Filings

Ticker · 397030 ISIN · KR7397030008 KO Professional, scientific and technical activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2023-09-11 Major Shareholding Noti…
Country KR South Korea
Listing KO 397030

About AprilBio Co.,Ltd.

http://www.aprilbio.com/en/

AprilBio is a biotechnology company that develops innovative biologic drugs, including therapeutic antibodies and recombinant proteins. The company's core is its proprietary SAFA (anti-Serum Albumin Fab-Associated) platform technology, which utilizes an albumin-binding antibody fragment to create long-acting therapeutics. This platform is designed to enhance the efficacy, safety, and plasma half-life of drug candidates while minimizing adverse effects. AprilBio's research and development pipeline focuses on addressing unmet medical needs in therapeutic areas such as autoimmune diseases, oncology, and other inflammatory and rare diseases. The company advances new drug candidates through early clinical development stages for potential technology transfer.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease due to market sales) by SJ Investment Partners and its related funds in the company AprilBio. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2023-09-11 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short regulatory announcement (under 1,000 characters) notifying the public of an upcoming Investor Relations (IR) event. It provides the date, time, location, and purpose of the meeting. According to the 'Menu vs Meal' rule, since this is an announcement of an event rather than the presentation materials themselves, it falls under the category of a regulatory filing or announcement. Given the specific nature of the notice regarding an IR event, 'RNS' (Regulatory Filings) is the most appropriate classification.
2023-08-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their personal share transactions or changes in ownership. According to the provided definitions, this falls under 'Director's Dealing' (DIRS).
2023-08-18 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '주식회사 에이프릴바이오' covering the period from January 1, 2023, to June 30, 2023. It contains comprehensive financial and business information, including company overview, business activities, and financial data. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim/Quarterly Report (IR). H1 2023
2023-08-14 Korean
전환가액의조정(제1회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price from 25,655 KRW to 20,271 KRW due to market price fluctuations. This type of filing relates to capital structure changes and financing instruments. Since it specifically details the adjustment of conversion terms for existing debt/equity instruments, it falls under the 'Capital/Financing Update' category.
2023-07-21 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'AprilBio Co., Ltd.' covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, and corporate governance data, which is characteristic of an interim/quarterly financial report. It is not a mere announcement or certification, but the full report itself. Q1 2023
2023-05-12 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.